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Aim: Disorders in the metabolism of homocysteine and B vitamins, which are involved in a one-carbon transfer reaction and important 
for DNA synthesis and methylation, have been hypothesized to be associated with carcinogenesis. The purpose of this study is to evalu-
ate the levels of homocysteine, vitamin B12 and folic acid in patients with newly diagnosed lung cancer and determines whether they 
might be used as an accurate tumor marker for monitoring the patients if they are found to be elevated in lung cancer. Materials and 
Methods: Forty male patients with lung cancer were included in this study. Age-matched forty healthy males who had not malignant 
disease or had not received any drug affecting plasma homocysteine levels were selected as control group. Homocysteine, vitamin B12 and 
folate levels were measured in the samples obtained from the patients and controls. Results: Mean age of the patients with lung cancer 
was 58.7 ± 9.9 years. All the patients were cigarettes smokers. Mean daily consumption of cigarettes was 2.0±0.7 packs and mean 
duration of smoking was 30 ± 11 years. Histologic type of carcinoma was found to be squamous cell carcinoma in 55%, 
adenocarcinoma — in 35%, and small cell carcinoma — in 10% of the cases. Clinical stage was stage IA in 20%, stage IB — in 20%, 
stage IIA — in 2.5%, stage IIB — in 10%, stage IIIA — in 12.5%, stage IIIB — in 20%, and stage IV — in 15% of the cases. Mean 
homocysteine level was 15.3 ± 7.3 μmol/l in the patients with lung cancer while 9.8 ± 2.6 μmol/l in controls. Homocysteine level was 
significantly higher in the patients with lung cancer compared to control group (p < 0.001). Mean folate level was 4.3 ± 1.8 pg/ml in cancer 
cases while 6.1 ± 2.3 pg/ml in controls. That is to say, plasma folate levels were significantly lower in cases of lung cancer compared 
to controls (p < 0.001). There was no significantly difference between groups with regard to B12 levels (mean B12 level was 234 ± 99 and 
240 ± 104 ng/ml in the patients with lung cancer and controls, respectively, p = 0.78). Plasma homocysteine, vitamin B12 and folate 
levels did not show significant difference with respect to histologic type of carcinoma. No significant correlation was found between 
plasma homocysteine, vitamin B12, folate levels and number of cigarettes smoked per day, duration of smoking, age of the patient, and 
clinical stage of carcinoma. There was also no correlation between number of cigarettes smoked per day, duration of smoking, age 
of the patient and clinical stage of carcinoma. A possible inverse correlation between plasma homocysteine, vitamin B12 and folate 
levels was not observed. Conclusion: In conclusion, high plasma homocysteine and low folate levels could be associated with lung 
cancer. However, further studies performed on large patient population are needed.
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Lung cancer is the leading cause of cancer mor-
tality worldwide. In 2014, 224,201 new patients will 
be diagnosed with lung cancer and 159,260 deaths 
from lung cancer will occur in the States [1]. A majo-
rity of the annual new diagnoses (83.4%) will be dead 
in 5 years after the diagnosis [2].
Homocysteine (Hcy), a naturally formed non-
protein α-amino acid, forms cystathione by combining 
with serine, which is then hydrolyzed to α-ketobutyrate 
and cysteine. Hcy is not acquired from the diet, instead 
it is biosynthesized from and recycled to essential 
amino acid methionine depending on whether the me-
thionine balance is negative or positive. If the ba-
lance is positive, then Hcy is converted to cysteine 
via transsulfuration through two different enzymes, 
cystathionine synthase and cystathionase, require 
vitamin B6 as a cofactor. On the other hand, in case 
of shortage of methionine, Hcy accepts a methyl group 
from N5-methylthetrahydrofolate (N5-methyl-THF) 
in a reaction that uses methylcobalamin, a coenzyme 
produced from vitamin B12, and Hcy methyltrans-
ferase and eventually is converted to methionine. 
Both cysteine and Hcy concentrations are regulated 
strictly. Folate and vitamin B12 are also involved in DNA 
methylation as well as in the synthesis of purines and 
thymidylate for DNA synthesis [3].
Detection of high levels of plasma Hcy, a well-
known risk factor for cardiovascular disease, has 
also been correlated with the development of cancer, 
in which folate has been suggested to play a pivotal 
role [4–6]. It was shown that in folate deficient rats 
DNA breaks and hypomethylation within the p53 tumor 
suppressor gene occured [7]. Not only does folate 
deficiency inhibit purine synthesis but it also decreases 
the cellular concentration of thymine, an essential 
component of DNA, by preventing methylation of de-
oxyuridinemonophosphate (dUMP) to deoxythymi-
dinemonophosphate (dTMP) [8]. Additionally, folate 
regulates DNA methylation by shifting cellular levels 
of SAM and thus controls gene expression. Global hy-
pomethylation secondary to folate deficiency has been 
shown in tumor DNA compared with normal tissue 
DNA [9]. On the other hand, accumulating evidence 
suggests that hypermethylation results in the suppres-
sion of carcinogenesis. DNA methylation changes have 
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been detected in early adenomas of colorectal cancer 
and prostate cancer [10, 11]. Furthermore, Piyathilake 
et al. [12] have shown the effects of folate deficiency 
on DNA hypomethylation in squamous cell lung cancer. 
In addition to these studies, it has been reported that 
folate has a protective effect against cervical cancer 
due to its clear role in DNA synthesis and repair [13].
Because Hcy significantly speeds up oxidation 
and free radical production, high levels of plasma Hcy 
have been shown to correlate with chromosomal injury 
through direct damage of the excess amount of these 
reactive oxygen products [14]. Mutations in genes, 
such as p53, occur as a result of DNA oxidation, which 
in turn might causes cancer development. Additionally, 
free oxygen radicals might precipitate DNA damage 
by impairing DNA methylation. Global DNA hypome-
thylation may lead to loss of chromosomes that results 
in the formation of micronucleus frequency (MN), 
which might be used as an indication of genotoxicity 
and aneuploidy [15].
The correlation between Hcy, relevant vitamins and 
cancer has been so far investigated mostly in colon, 
breast and pancreatic cancer [5, 16, 17]. The reports 
studying this matter on lung cancer are rare. The pur-
pose of this study is to evaluate the levels of Hcy, vita-
min B12 and folic acid in patients with newly diagnosed 
lung cancer and determine whether they might be used 
as an accurate tumor marker for monitoring the pa-
tients if they are found to be elevated in lung cancer.
MATERIALS AND METHODS
In this retrospective study, we reviewed the data 
of 40 men who were diagnosed with lung cancer. All 
patients were evaluated by imaging techniques (chest 
radiography or computed tomography). The diagnosis 
was made via bronchoscopy and biopsy on suspi-
cious lesions. All the patients were newly diagnosed 
lung cancer patients and have not received any 
surgical treatment, radiotherapy or chemotherapy. 
Demographic characteristics of the patients (age, 
smoking history, occupation, family history of cancer 
and history of tuberculosis), and histology and stage 
of the cancer were recorded. Age- and sex-matched 
40 healthy controls were enrolled in the study. Hcy, 
vitamin B12 and folate levels were measured in blood 
samples from the patients and control groups. Patients 
and the control group avoided medications that had 
potential effects to alter Hcy levels.
This study was approved by local ethical commit-
tee. Informed consent was obtained from each subject 
in the hospital.
Blood sampling. 3 ml of blood were drawn from 
antecubital veins of both the patients and the control 
group in the morning before breakfast and they were 
put into K3 EDTA tubes. K3 EDTA tubes were then 
centrifuged at 2500/g for 5 min. No hemolysis oc-
curred in the samples. Plasma samples were removed 
and transferred to an eppendorf tube. Examples were 
numbered and stored at −80 °C until analysis.
Analysis of plasma Hcy. Plasma Hcy levels were 
measured by High Performance Liquid Chromato-
graphy (HPLC) method. 100 μl of plasma, 25 μl of in-
ternal standard and 25 μl of reduction reagent were 
mixed in a 1.5 ml plastic eppendorf tubes. Stirring 
gently, the mixture was incubated at room tempera-
ture for 5 min. Then 100 μl precipitant reagent was 
added and mixed for 30 s. The mixture was centri-
fuged at 9000/g for 7 min. 50 μl supernatants of all 
samples were taken to another eppendorf tube and 
100 μl of derivatizing reagent were added. It was incu-
bated at 55 °C for 10 min. It was removed from the water 
bath and transferred to the sample vessels. HPLC 
equipment was programmed to take 20 μl of the su-
pernatant automatically. Analysis of each sample was 
completed in 6 min. Results were given as μmol/l.
The Intra-assay and Inter-assay Reproducibi-
lity Study. Each parameter was studied for 10 times 
consecutively in relation to the intraday reproducibility 
study for Hcy. For the inter-day reproducibility, each 
parameter was studied for 10 times in different days 
or different sessions on the same day.
Other biochemical analysis. Vitamin B12 and folic 
acid levels of patient and control group were measured 
by Immulate DPC Immunoassay (Los Angeles, USA) 
device with using Immulate DPC kits.
Statistical analysis. Statistical evaluations 
of the findings obtained from our study were per-
formed in SPSS 18.0 software package. The mean 
values and standard deviation of the parameters were 
calculated. Student t-test was used to assess the 
differences between the two groups while the differ-
ences between the three groups were evaluated with 
ANOVA test. Pearson’s correlation test was performed 
for the correlation analysis. p < 0.05 was considered 
statistically significant.
RESULTS AND DISCUSSION
The study included 40 male patients with lung 
cancer and age-matched 40 healthy men. The mean 
age of the patients was 58.7 ± 9.9 years (median: 
58, range: 38–78). All of the cases were smokers. 
The average of the daily cigarette consumption was 
2 ± 0.7 packs (median: 2, range: 1–4), and the average 
numbers of years of smoking was 30 ± 11 (median: 29, 
range: 10–58).
Of the patients, 55% had squamous cell carcinoma, 
35% had adenocarcinoma and 10% had small cell car-
cinoma. 20% of the cases were in stage II, 20% were 
in stage IB, 2.5% were in stage III, 10% were in stage 
IIB, 12.5% were in stage IIIA, 20% were in stage IIIB 
and 15% were in stage IV.
The mean Hcy level of the patients with lung can-
cer was 15.3 ± 7.3 μmol/l (median: 14.8 and range: 
5.0–36.2), while it was 9.8 ± 2.6 μmol/l (median: 
10.1 and range 4.2–13.4) in the control group. Hcy 
levels were significantly higher in lung cancer patients 
compared with the control group (p < 0.001). The mean 
plasma folate levels were 4.3 ± 1.8 pg/ml (median: 
3.8 and range: 1.9–7.9) in patients with lung cancer 
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whereas it was 6.1 ± 2.3 pg/ml (median: 6.1 and range: 
2.4–11.5) in the control group. Accordingly, the plasma 
folate levels were significantly lower in lung cancer 
patients than in controls (p < 0.001). No significant 
differences were detected between the two groups 
in terms of vitamin B12 levels (for patients with lung 
cancer mean: 234 ± 99 ng/ml, median: 226, range: 
154–797; for the controls mean: 240 ± 104 ng/ml, 
median: 208, range: 100–539 and p = 0.78). The levels 
of plasma Hcy, folate and vitamin B12 in cancer patients 
and controls were shown in Table. No difference was 
observed in the plasma Hcy, folate and vitamin B12 le-
vels according to histological type.
Table. Plasma Hcy, folate and vitamin B12 levels in lung cancer patients 
and the healthy controls
Indexes
Patient group
plung cancer patients 
(n = 40)
controls 
(n = 40)
Hcy, μmol/l 15.3 ± 7.3 9.8 ± 2.6 < 0.001
Folate, pg/ml 4.3 ± 1.8 6.1 ± 2.3 < 0.001
Vitamin B12, ng/ml 234 ± 99 240 ± 104 0.78
Note: values were shown as mean ± SD.
There was not a significant correlation between 
plasma Hcy, folate and vitamin B12 levels and num-
ber of cigarettes smoked daily, the total duration 
of smoking, age and stage of cancer. There was not 
a significant relationship between the disease stage 
and the number of cigarettes smoked daily, the total 
duration of smoking and age of the patients. Likewise, 
a significant inverse correlation was not detected be-
tween plasma Hcy levels and folate, vitamin B12 levels 
in contrast to expected. As predictable, a significant 
positive correlation was present between age and 
duration of smoking (p = 0.001).
There have been numerous studies investigating 
the association between cancer and serum vitamins 
B6, B12, folate and Hcy. Deficiency in folate has been 
shown to increase the risk of cervical, colorectal, 
lung, esophagus, brain, pancreas and breast cancer 
in epidemiological, clinical and experimental stu-
dies [18]. Large prospective epidemiological studies 
have determined an inverse dose-dependent relation-
ship between dietary folate intake and cancer risk; 
that folate supplementation could reverse cervical 
dysplasia and moderately increased amount of di-
etary folate or sufficient serum folate levels reduced 
the risk of pancreatic and breast cancer [16, 17, 19, 
20]. However, in a recently published metaanalysis 
of data on 50,000 individuals concluded that folic 
acid supplementation had no impact on overall and 
site-specific cancer incidence [21].
Studies suggest that there is an inverse correlation 
between folate status in the body and the development 
of lung cancer [22]. Two randomized controlled trials 
have shown improvement of atypia in patients with 
bronchial squamous cell metaplasia with folate and 
vitamin B12 therapy. In addition, plasma folate levels 
in smokers with metaplasia were significantly lower 
than those in smokers without metaplasia [23, 24]. 
Bandera et al. [25] (New York State Cohort Study) have 
investigated the relationship between the risk of lung 
cancer and diet. This cohort study in which 27,544 men 
and 20,456 women participated, men with low amount 
of dietary vitamin C, carotenoids and folate intake were 
found to have increased risk of lung cancer. Similar 
results have been identified by Voorrips et al. [26] 
in a large epidemiological study (Netherlands Cohort 
Study). Furthermore, in a metaanalysis it has been de-
termined that both folate intake and high serum folate 
levels were significantly associated with reduced risk 
of lung cancer [27]. On the other hand, in a recently 
published metaanalysis of 9 cohort studies including 
566,921 individuals have shown that folate intake did 
not have as much impact on the risk of lung cancer 
as expected. Another suprising result of this study 
was that low folate intake might have a protective role 
on women whereas high folate intake plays a protective 
role on men [28]. However, a 16-year prospective co-
hort study on 1,793,327 women (Nurses’ Health Study) 
has failed to show an association between lung cancer 
and the amount of folate in the diet [29]. Similarly, 
the metaanalysis of the randomized controlled trials 
have pointed out that folic acid supplementation has 
no significant effect on overall cancer incidence [30].
Pyridoxal-5´-phosphate (PLP), the bioactive form 
of vitamin B6, is substantial for the catabolism of Hcy. 
Thus, reduced circulating levels of B6 vitamin result 
in hyperhomocysteinemia. It has been identified that 
higher levels of pyridoxal kinase (PDXK), the enzyme 
that activates B6 vitamin by converting it into PLP, 
is a therapy-independent prognostic marker in patients 
with non-small cell lung carcinoma [31]. The double-
blind, placebo-controlled study by Hartman et al. [32] 
has found that the risk of lung cancer was significantly 
lower in men with higher vitamin B6 levels. It was the first 
report of vitamin B6 role in lung cancer. In addition, 
in a population-based, prospective cohort study in-
cluding 74,941 women who have never smoked, it was 
reported that dietary riboflavin intake and a higher than 
median intake of methionine were inversely associated 
with lung cancer risk whereas no such relationship was 
found with other B vitamins [33]. Similar results were 
shown for riboflavin in current smokers in the Mel-
bourne Collaborative Cohort Study that comprised 
41,514 indiduals whereas there was no such correlation 
in individuals who previously smoked and who never 
smoked, and there was no such correlation for other 
B vitamins or for methionine [34]. On the other hand, 
in the European Prospective Investigation into Cancer 
and Nutrition (EPIC) study including 519,978 par-
ticipants, higher serum levels of B6 and methionine 
were associated with reduced lung cancer risk in all 
of never, former, and current smokers while lower 
risk of lung cancer was correlated with higher serum 
folate only in former and current smokers [35]. In con-
trast to these fin dings, in Norwegian Vitamin Trial and 
Western Norway B Vitamin Intervention Trial including 
6,837 patients with ischemic heart disease, folic acid 
plus vitamin B12 intake was correlated with increased 
cancer incidence, cancer mortality (especially in lung 
cancer), and all-cause mortality [36].
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The present study showed that plasma folate 
levels were significantly lower in patients with newly 
diagnosed lung cancer compared to age- and 
sex-matched healthy controls. This result supports 
the suggestion that reduced folate status is associated 
with increased risk of lung cancer. However, no such 
difference was detected for vitamin B12 levels.
In a current study, a structural equation modeling 
put together four different kinds of variable including 
methionine-homocysteine metabolism, folate cycle, 
transsulfuration, and immune activation and pointed 
out their complex relationship with each other in lung 
cancer carcinogenesis [37]. In that study, it was 
argued that methionine-homocysteine metabolism 
and immune activation had a stronger association 
with the lung cancer risk than did the other potential 
mechanisms. In another study, it was shown that in-
creased cancer-related death risk was significantly 
associated with high Hcy levels [4]. Furthermore, cer-
vical intraepithelial neoplasia was found to be in a posi-
tive correlation with high Hcy levels [6]. The patients 
with Hcy levels in the highest quartile (12.2 mmol/l) 
have been reported to have increased cancer risk 
by 70% compared to patients with the lowest quartile 
(≤7.9 mmol/l) [5]. It was shown that disorders in Hcy 
metabolism were associated with colon, breast and 
pancreatic cancers [5, 16, 17, 19].
In our study, the finding that plasma Hcy levels 
in lung cancer patients were significantly higher 
than those in controls, has supported the view that 
hyperhomocysteinemia was an important risk factor 
for lung cancer development. Although serum Hcy 
concentration was shown to be inversely proportional 
to serum folate, vitamins B6 and B12 levels in a previous 
study, there was not a significant inverse relationship 
between Hcy and folate or vitamin B12 levels in our 
study [38]. In another study, in accordance with our 
results a significantly higher t-Hcy, lower t-Glutathion 
 and folate levels were found in the advanced-stage 
group compared with those in the control group [39]. 
In our study, the result that the levels of folate were low 
while vitamin B12 levels were normal might be explained 
by the fact that folate was a more important factor 
in Hcy metabolism than vitamin B12.
High Hcy level in patients with lung cancer might 
be used as a sensitive marker for early diagnosis and 
detection of recurrences. However, since Hcy rises 
in other tumors types and the sensitivity and specificity 
of Hcy have not been determined in this study, a more 
precise statement is yet to be made.
A correlation between plasma Hcy, folate, vitamin 
B12 levels and the number of cigarettes smoked per 
day, total time of smoking and the histological type 
of cancer could not be detected. Bandera et al. [25] 
found in a fairly large population that lower folate lev-
els increased the risk of lung cancer. This increased 
risk was more associated with squamous cell cancer 
compared to adenocarcinoma. Furthermore, this 
risk was increased more significantly in people who 
consumed a larger amount of cigarettes (>20/day). 
In our study, in contrast to these results, no relationship 
between folate and either smoking or histological type 
of the lung cancer was determined.
In conclusion, significantly higher plasma Hcy and 
lower folate levels was found in lung cancer patients 
compared to controls whereas there was no difference 
in B12 levels between two groups. In order to evalu-
ate the value of plasma Hcy levels in lung cancer 
as a marker, further studies with larger number of pa-
tients are required.
REFERENCES
1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. 
CA Cancer J Clin 2014; 64: 9–29.
2. Howlader N, Noone AM, Krapcho M, et al. (eds). 
SEER Cancer Statistics Review, 1975–2009 (Vintage 
2009 Populations) based on November 2011 SEER data 
submission. Bethesda, MD: National Cancer Institute; 2012.
3. Bailey LB, Gregory JF 3rd. Folate metabolism and 
requirements. J Nutr 1999; 129: 779–82.
4. Kark JD, Selhub J, Adler B, et al. Nonfasting plasma 
total homocysteine level and mortality in middle-aged and 
elderly men and women in Jerusalem. Ann Intern Med 1999; 
131: 321–30.
5. Kato I, Dnistrian AM, Schwartz M, et al. Serum folate, 
homocysteine and colorectal cancer risk in women: a nested 
case-control study. Br J Cancer 1999; 79: 1917–22.
6. Thomson SW, Heimburger DC, Cornwell PE, et al. 
Correlates of total plasma homocysteine: folic acid, copper, 
and cervical dysplasia. Nutrition 2000; 16: 411–6.
7. Kim YI, Pogribny IP, Basnakian AG, et al. Folate defi-
ciency in rats induces DNA strand breaks and hypomethylation 
within the p53 tumor suppressor gene. Am J Clin Nutr 1997; 
65: 46–52.
8. Blount BC, Mack MM, Wehr CM, et al. Folate defi-
ciency causes uracil misincorporation into human DNA and 
chromosome breakage: implications for cancer and neuronal 
damage. Proc Natl Acad Sci USA 1997; 94: 3290–5.
9. Habib M, Fares F, Bourgeois CA, et al. DNA global 
hypomethylation in EBV-transformed interphase nuclei. Exp 
Cell Res 1999; 249: 46–53.
10. Hernandez-Blazquez FJ, Habib M, Dumollard JM, 
et al. Evaluation of global DNA hypomethylation in human 
colon cancer tissues by immunohistochemistry and image 
analysis. Gut 2000; 47: 689–93.
11. Santourlidis S, Florl A, Ackermann R, et al. High fre-
quency of alterations in DNA methylation in adenocarcinoma 
of the prostate. Prostate 1999; 39: 166–74.
12. Piyathilake CJ, Johanning GL, Macaluso M, et al. 
Localized folate and vitamin B-12 deficiency in squamous cell 
lung cancer is associated with global DNA hypomethylation. 
Nutr Cancer 2000; 37: 99–107.
13. Butterworth CE Jr. Effect of folate on cervical cancer. 
Synergism among risk factors. Ann NY Acad Sci USA 1992; 
669: 293–9.
14. Oikawa S, Murakami K, Kawanishi S. Oxidative da-
mage to cellular and isolated DNA by homocysteine: implica-
tions for carcinogenesis. Oncogene 2003; 22: 3530–8.
15. Crott J, Fenech M. Preliminary study of the genotoxic 
potential of homocysteine in human lymphocytes in vitro. 
Mutagenesis 2001; 16: 213–7.
16. Zhang S, Hunter DJ, Hankinson SE, et al. A prospec-
tive study of folate intake and the risk of breast cancer. JAMA 
1999; 281: 1632–7.
222 Experimental Oncology 37, 218–222, 2015 (September)
17. Stolzenberg-Solomon RZ, Albanes D, Nieto FJ, et al. 
Pancreatic cancer risk and nutrition-related methyl-group 
availability indicators in male smokers. J Natl Cancer Inst 
1999; 91: 535–41.
18. Mason JB, Levesque T. Folate: effects on carcinogene-
sis and the potential for cancer chemoprevention. Oncology 
(Huntingt) 1996; 10: 1727–36.
19. Glynn SA, Albanes D, Pietinen P, et al. Colorectal can-
cer and folate status: a nested case-control study among male 
smokers. Cancer Epidemiol Biomarkers Prev 1996; 5: 487–94.
20. Butterworth CE Jr, Hatch KD, Gore H, et al. Impro-
vement in cervical dysplasia associated with folic acid therapy 
in users of oral contraceptives. Am J Clin Nutr 1982; 35: 73–82.
21. Vollset SE, Clarke R, Lewington S, et al. B-Vitamin 
Treatment Trialists’ Collaboration. Effects of folic acid supple-
mentation on overall and site-specific cancer incidence during 
the randomised trials: meta-analyses of data on 50,000 indivi-
duals. Lancet 2013; 381: 1029–36.
22. Jatoi A, Daly BD, Kramer G, et al. Folate status among 
patients with non-small cell lung cancer: a case-control study. 
J Surg Oncol 2001; 77: 247–52.
23. Heimburger DC, Alexander CB, Birch R, et al. Improve-
ment in bronchial squamous metaplasia in smokers treated with 
folate and vitamin B12. Report of a preliminary randomized, 
double-blind intervention trial. JAMA 1988; 259: 1525–30.
24. Saito M, Kato H, Tsuchida T, et al. Chemoprevention 
effects on bronchial squamous metaplasia by folate and vita-
min B12 in heavy smokers. Chest 1994; 106: 496–9.
25. Bandera EV, Freudenheim JL, Marshall JR, et al. Diet 
and alcohol consumption and lung cancer risk in the New 
York State Cohort (United States). Cancer Causes Control 
1997; 8: 828–40.
26. Voorrips LE, Goldbohm RA, Brants HA, et al. A pros-
pective cohort study on antioxidant and folate intake and male 
lung cancer risk. Cancer Epidemiol Biomarkers Prev 2000; 
9: 357–65.
27. Dai WM, Yang B, Chu XY, et al. Association between 
folate intake, serum folate levels and the risk of lung can-
cer: a systematic review and meta-analysis. Chin Med J (Engl) 
2013; 126: 1957–64.
28. Zhang YF, Zhou L, Zhang HW, et al. Association 
between folate intake and the risk of lung cancer: a dose-
response meta-analysis of prospective studies. PLoS One 
2014; 9: e93465.
29. Speizer FE, Colditz GA, Hunter DJ, et al. Prospective 
study of smoking, antioxidant intake, and lung cancer in middle-
aged women (USA). Cancer Causes Control 1999; 10: 475–82.
30. Qin X, Cui Y, Shen L, et al. Folic acid supplementa-
tion and cancer risk: a meta-analysis of randomized controlled 
trials. Int J Cancer 2013; 133: 1033–41.
31. Galluzzi L, Vacchelli E, Michels J, et al. Effects of vi-
tamin B6 metabolism on oncogenesis, tumor progression and 
therapeutic responses. Oncogene 2013; 32: 4995–5004.
32. Hartman TJ, Woodson K, Stolzenberg-Solomon R, 
et al. Association of the B-vitamins pyridoxal 5´-phosphate 
(B(6)), B(12), and folate with lung cancer risk in older men. 
Am J Epidemiol 2001; 153: 688–94.
33. Takata Y, Cai Q, Beeghly-Fadiel A, et al. Dietary 
B vitamin and methionine intakes and lung cancer risk among 
female never smokers in China. Cancer Causes Control 2012; 
23: 1965–75.
34. Bassett JK, Hodge AM, English DR, et al. Dietary 
intake of B vitamins and methionine and risk of lung cancer. 
Eur J Clin Nutr 2012; 66: 182–7.
35. Johansson M, Relton C, Ueland PM, et al. Serum B vi-
tamin levels and risk of lung cancer. JAMA 2010; 303: 2377–85.
36. Ebbing M, Bønaa KH, Nygård O, et al. Cancer inci-
dence and mortality after treatment with folic acid and vitamin 
B12. JAMA 2009; 302: 2119–26.
37. Baltar VT, Xun WW, Johansson M, et al. A structural 
equation modelling approach to explore the role of B vitamins 
and immune markers in lung cancer risk. Eur J Epidemiol 
2013: 28: 677–88.
38. Selhub J, Jacques PF, Wilson PW, et al. Vitamin sta-
tus and intake as primary determinants of homocysteinemia 
in an elderly population. JAMA 1993; 270: 2693–8.
39. Ozkan Y, Yardim-Akaydin S, Firat H, et al. Usefulness 
of homocysteine as a cancer marker: total thiol compounds 
and folate levels in untreated lung cancer patients. Anticancer 
Res 2007; 27: 1185–9.
 Copyright © Experimental Oncology, 2015 
